Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart risk under the microscope: verapamil for cluster headaches

NCT ID NCT04406259

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how often a common heart side effect (first-degree atrioventricular block) occurs when verapamil is used at high doses to prevent cluster headaches. Researchers will monitor 60 patients starting or already on verapamil, using ECGs and blood tests. The goal is to better understand and track these heart conduction issues, not to test if verapamil works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Verapamil
What this could lead to
If successful, this could help doctors better understand and manage the heart-related side effects of high-dose verapamil when used for cluster headache prevention.
What could go wrong
This is a small, observational study focused on side effects, not on whether verapamil works for headaches. It may not lead to new treatments or change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patient 18 years old, and older * patient suffering from Cluster Headache (according to the l'ICHD-3 diagnostic criterias) * patients affiliated to the social security * patient that has given his full written consent to participate in the study * female patients participating in the study must be using an efficient contraception for more than 1 month prior to the beginning of the study Exclusion Criteria: * patient presenting contraindications to the use of verapamil * patient observing a treatment with ivabradine (Procoralan®), bétablockers, colchicine, l'esmolol, triazolam, quinidine. * patient under justicial protection * patient breastfeeding, or pregnant * patient suffering from a neuromuscular transmisson disease * patient with a pacemaker

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cluster headache are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cluster headache syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cluster headache

Contacts and locations

Locations

  • AP-HP Hôpital la Timone

    Marseille, 13005, France

  • CHU de Nice

    Nice, CHUN, 06003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.